Hypofractionated radiotherapy for glioblastoma: correlation with prognostic factors and survival outcomes
Year: 2025
Type: article
Abstract: Purpose: To evaluate the efficacy of hypofractionated radiotherapy (HFRT) followed by conventional fractionated radiotherapy (CFRT) in glioblastoma multiforme (GBM) patients and identify prognostic factors. Methods: A retrospective analysis of 120 GBM patients treated postoperatively between 2010 and 2017 with HFRT (30 Gy in 3 Gy fractions) followed by CFRT (24 Gy in 2 Gy fractions), for a total dose of 60 Gy. All patients received concurrent and adjuvant Temozolomide (TMZ). Results: Median age was 62.5 years. Median overall survival (OS) was 11.3 months; 1-, 2-, and 3-year survival rates were 43.3%, 16.1%, and 4.6%, respectively. Full dose completion correlated with improved OS (12.2 vs. 7.3 vs. 4.6 months for ≥100%, 90–99%, and < 70% dose realization, respectively). Age ≤63 years and GTV ≤44.5 cm³ were associated with significantly better survival. Gender had no significant impact. Conclusions: HFRT followed by CFRT with TMZ is an effective alternative to standard CFRT in patients with subtotal or partial resection. Age and tumor volume are independent prognostic factors for overall survival.
DOI: 10.5603/rpor.108278
Authors: Dimcho Georgiev, Svetlana Bilyukova, Cyril Kounin
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,713
OpenAlex ID: W7102652209